Product Images Raloxifene Hydrochloride

This document presents data on the percentage change in total hip bone mineral density (BMD) from baseline in subjects who received either placebo or raloxifene hydrochloride (a medication used to prevent osteoporosis) over a 24-month period. The results are shown in Figure 1, with separate data presented for studies conducted in North America and Europe and for hysterectomized women taking conjugated estrogens (CE). The data is analyzed using an "intent to treat" approach with last observation carried forward.*

This is a description of Raloxifene Hydrochloride, a prescription medication distributed by Aurobindo Pharma USA Inc. The tablets contain 60mg of Raloxifene hydrochloride USP and come packaged with a Medication Guide to be given to each patient. The recommended adult dosage is included in the package literature. The tablets should be stored in a tight container at controlled room temperature. If the inner seal is missing or broken, do not use. No non-English characters were detected.*

This is a package of Raloxifene Hydrochloride tablets containing 30 unit-dose tablets each. The tablets are USP approved, and each film-coated tablet contains Raloxifene hydrochloride. The tablets are stored at 20° to 25°C (68° to 77°F), and the package is not child-resistant. The medication guide is provided separately to each patient. The package also includes dosage instructions for adults and a warning not to print on the dotted lines.*